ERBB2 and glioblastoma: In various cancer models, including glioblastoma and HER-2 positive breast cancer, CXCR4 inhibition reduced tumor growth, invasion, metastasis, and stromal cell recruitment, highlighting its key role in tumor progression and the TME25,42,43.